[Annular elastolytic giant cell granuloma].
BACKGROUND
Annular elastolytic giant cell granuloma (AEGCG) is a rare form of granulomatous dermatosis. It is characterised histologically by phagocytosis of elastic fibres by multinucleated cells. We report a favourable outcome in a case of AEGCG following PUVA therapy and treatment with synthetic antimalarials.


METHODS
A 67-year-old retired wine grower presented with highly pruritic annular lesions with raised borders on the shoulders and trunk that had been present for several months. Histological examination of a biopsy sample from the erythematous border was characteristic of AEGCG. Various topical treatments proved ineffective and systemic corticosteroids attenuated the patient's pruritus but had no effect on the skin lesions. PUVA therapy resulted in regression of lesions on the trunk, but the rash spread to the patient's arms and was covered with epidermal microcysts. PUVA therapy was discontinued and treatment with a synthetic antimalarial (hydroxychloroquine 400mg/d) was initiated, resulting in complete regression of the lesions.


CONCLUSIONS
AEGC was isolated in 1979 by Hanke et al. on the basis of five cases seen in females. This is a rare form of dermatosis with some 30 cases being reported in the English literature. The clinical aspect is fairly evocative, with erythematous papular lesions, either alone or in groups, with a raised border and a lighter centre tending towards atrophy. In most cases, the lesions are found predominantly in areas exposed to sunlight. The histological appearance is characteristic, with an image of giant cell elastophagic granuloma from which the name of the disease is taken. This appearance allows the disease to be differentiated from a number of other granulomatous diseases. The aetiology is unknown and treatment is empirical. Spontaneous cure can occur and consistent results have not been obtained with any treatments. In our case, PUVA was partly successful, and the synthetic antimalarials resulted in complete regression of residual lesions.
Djilali-Bouzina
F
F
Service de dermatologie, hôpital Pasteur, Colmar cedex, France. jc.guillaume@wanadoo.fr
Grange
F
F
Krzisch
S
S
Schnebelen
M-P
MP
Grosshans
E
E
Guillaume
J-C
JC
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000368:Aged; D000962:Antimalarials / Q000627:therapeutic use; D000982:Antipruritics / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D004547:Elastic Tissue / Q000473:pathology*; D016460:Granuloma Annulare / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D006101:Granuloma, Giant Cell / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D006391:Hemangioma / Q000150:complications; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D033162:Incidental Findings; D008113:Liver Neoplasms / Q000150:complications; D008297:Male; D011701:PUVA Therapy; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology
D000305:Adrenal Cortex Hormones; D000962:Antimalarials; D000982:Antipruritics; D006886:Hydroxychloroquine